Suppliers and packagers for PULMICORT RESPULES

PULMICORT RESPULES

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca	PULMICORT RESPULES	budesonide	SUSPENSION;INHALATION	020929	NDA	AstraZeneca Pharmaceuticals LP	0186-1988-04	6 POUCH in 1 CARTON (0186-1988-04) / 5 AMPULE in 1 POUCH / 2 mL in 1 AMPULE	2000-09-08
Astrazeneca	PULMICORT RESPULES	budesonide	SUSPENSION;INHALATION	020929	NDA	AstraZeneca Pharmaceuticals LP	0186-1989-04	6 POUCH in 1 CARTON (0186-1989-04) / 5 AMPULE in 1 POUCH / 2 mL in 1 AMPULE	2000-09-08
Astrazeneca	PULMICORT RESPULES	budesonide	SUSPENSION;INHALATION	020929	NDA	AstraZeneca Pharmaceuticals LP	0186-1990-04	6 POUCH in 1 CARTON (0186-1990-04) / 5 AMPULE in 1 POUCH / 2 mL in 1 AMPULE	2007-09-17

Suppliers for the Pharmaceutical Drug: PULMICORT RESPULES

Last updated: August 5, 2025

Introduction

Pulmicort Respules (budesonide inhalation suspension) are a prescription medication primarily used for managing asthma in pediatric patients, especially those below 12 months and young children unable to use traditional inhalers. As a vital therapy in respiratory care, the global demand for Pulmicort Respules has surged, prompting various pharmaceutical suppliers to participate in its manufacturing and distribution. This article offers an in-depth analysis of the primary suppliers of Pulmicort Respules, their manufacturing capacities, regulatory adherence, and market strategies, enabling healthcare professionals, distributors, and investors to understand the drug’s supply landscape.

---

Overview of Pulmicort Respules

Pulmicort Respules have been marketed by AstraZeneca since their approval, becoming a leading inhaled corticosteroid for pediatric asthma management. The formulation comprises budesonide, a potent anti-inflammatory agent delivered via a nebulizer. Its inhalation suspension form is particularly significant for young children who cannot efficiently use metered-dose inhalers (MDIs). The demand for Pulmicort Respules is driven by the increased prevalence of pediatric asthma worldwide, especially in urbanized regions with environmental pollutants contributing to respiratory conditions.

---

Primary Suppliers and Manufacturing Landscape

1. AstraZeneca – The Original Manufacturer

AstraZeneca remains the initial and primary supplier of Pulmicort Respules globally. The company maintains manufacturing facilities adhering to stringent Good Manufacturing Practices (GMP) at various sites, notably in the UK, Sweden, and the United States. AstraZeneca’s manufacturing process encompasses complex formulation and filling procedures critical for the stability and efficacy of nebulized suspensions. Their extensive distribution network ensures a steady supply across North America, Europe, Asia, and other regions.

2. Contract Manufacturing Organizations (CMOs)

With the rising global demand and the need for supply chain diversification, AstraZeneca and other pharmaceutical entities often partner with specialized CMOs to augment production capacities. These CMOs possess state-of-the-art facilities capable of large-scale aseptic filling of nebulized suspensions, adhering to international regulatory standards like FDA cGMP, EMA, and Japan’s PMDA.

• Recipharm (Sweden): Known for inhalation product manufacturing, Recipharm collaborates with global pharmaceutical companies to produce respiratory drug formulations, including nebulized drugs similar to Pulmicort Respules.
• CSPC Pharmaceutical Group (China): A prominent Chinese CMO that has expanded its respiratory medication manufacturing, potentially supplying generic or biosimilar inhalational corticosteroids.
• Viatris (formerly Mylan): Engages in contract manufacturing of respiratory products, and has partnered for inhaled corticosteroid production, though specific Pulmicort Respules manufacturing details are proprietary.

3. Regional Generic Manufacturers

Regulatory approval and patent expiration have prompted generic manufacturers to develop alternative formulations, especially in emerging markets.

• Glenmark Pharmaceuticals (India): Developed generic versions of budesonide inhalation suspensions, supplying regional markets under local regulatory approvals.
• Torrent Pharmaceuticals (India): Focused on inhalation products, including nebulized corticosteroids, with approved formulations in India and neighboring regions.
• Cipla (India): Supplies inhaled corticosteroids, aiming to meet regional demand and often manufacturing in partnership with global brands under licensing agreements.

While these generics are not labeled Pulmicort Respules (a trademarked product), they serve as critical suppliers in jurisdictions where AstraZeneca's patent protections are limited.

4. Emerging Market Suppliers

In African, Southeast Asian, and Latin American markets, several local and regional manufacturers have obtained licenses or have launched biosimilar/niche products to meet local demand.

• Sinphar Pharmaceutical Co. (Taiwan): Produces inhalation products, including budesonide suspensions, tailored for Asian markets.
• Aurobindo Pharma (India): Developing inhaled corticosteroid offerings in line with regulatory standards for these regions.

---

Regulatory and Quality Considerations

Manufacturers of Pulmicort Respules must comply with international regulatory standards like the US FDA's cGMP, EMA’s guidelines, and ISO certifications. These standards ensure product consistency, sterility, and bioavailability. AstraZeneca’s quality management systems guarantee supply chain integrity, while CMOs and generic manufacturers are often subject to rigorous audits prior to approval.

For distributors and healthcare providers, sourcing from approved suppliers with validated manufacturing practices is critical to prevent counterfeit and substandard products. The ability to trace the supply chain, verify batch documentation, and ensure compliance with local regulatory requirements are essential considerations.

---

Market Dynamics and Supply Chain Risks

The supply chain of Pulmicort Respules faces challenges, including manufacturing disruptions, raw material shortages—particularly for pharmaceutical-grade excipients and sterile components—and regional regulatory delays. The COVID-19 pandemic stressed global supply chains, prompting diversification strategies and increased inventory buffers among major suppliers.

Patent expirations in certain territories have enabled local manufacturers to produce biosimilars and generics, expanding supply but raising concerns about quality standards. Maintaining regulatory compliance and quality assurance remains pivotal for ongoing supply stability.

---

Emerging Trends Influencing Suppliers

• Biosimilar development: As patents expire, biosimilar inhaled corticosteroids are entering the market, fostering competition.
• Manufacturing innovation: Adoption of continuous manufacturing and advanced sterile filling technologies enhances capacity and quality.
• Supply chain localization: Countries increasingly favor local production to reduce dependence on imports, potentially affecting the global supplier landscape.
• Regulatory harmonization: International standards facilitate smoother approval processes across regions, enabling suppliers to expand faster.

---

Conclusion

The supply of Pulmicort Respules hinges heavily on AstraZeneca as the original manufacturer, supplemented by a network of contract manufacturers, generic producers, and regional players. Ensuring a resilient supply chain involves adherence to stringent quality standards, diversification of manufacturing sources, and strategic inventory management. Ongoing market and regulatory developments, including biosimilar entry and manufacturing innovations, will shape the future supply landscape.

---

Key Takeaways

• AstraZeneca dominates Pulmicort Respules supply but relies on CMOs and regional manufacturers to meet global demand.
• Regulatory compliance and quality assurance are non-negotiable pillars for supplier legitimacy and product safety.
• Emerging biosimilars and generics expand access but necessitate vigilance regarding quality and regulatory approval.
• Supply chain resilience depends on diversification, advanced manufacturing, and regional production strategies.
• Market shifts driven by patent expirations and regional licensing influence supplier participation and competition.

---

FAQs

1. Who are the main manufacturers of Pulmicort Respules globally?
AstraZeneca is the primary original manufacturer, complemented by contract manufacturing organizations like Recipharm and regional generic producers primarily based in India and China.

2. Are there approved biosimilar versions of Pulmicort Respules?
While biosimilars for inhaled corticosteroids are developing, no biosimilar has yet received widespread regulatory approval explicitly labeled as Pulmicort Respules. Generic equivalents or alternative formulations are available in some regions.

3. What should healthcare providers consider when sourcing Pulmicort Respules?
They should ensure procurement from authorized, regulatory-approved suppliers that comply with cGMP standards to guarantee safety, efficacy, and product integrity.

4. How is supply chain risk managed for Pulmicort Respules?
Through supplier diversification, robust inventory management, and adherence to regulatory standards, along with contingency planning for manufacturing disruptions.

5. What impact do patent expirations have on Pulmicort Respules supply?
Patent expirations facilitate the entry of generics and biosimilars, increasing supply options and potentially reducing costs, but also necessitating careful regulation to maintain quality standards.

---

References

[1] AstraZeneca. Pulmicort Respules Product Details.
[2] U.S. Food and Drug Administration. Good Manufacturing Practices.
[3] European Medicines Agency. Guidelines on the manufacture of inhalation products.
[4] Recipharm Corporate Website. Contract Manufacturing Capabilities.
[5] GlobalData. Respiratory Drug Market Analysis Q4 2022.